April 2015

Duvelisib (IPI-145) is an orally administered, dual inhibitor of phosphoinositide 3-kinase (PI3K) delta (δ) and gamma (γ) isoforms, and the drug is selective for PI3K class I isoforms over other lipid and protein kinases.